GlassScriptPhysician profile
Paul David Jayachandra
NPI 1417953076
$5,746.97
in general payments reported to CMS, 2019-2025
20 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $658 · 2021: $885 · 2022: $913 · 2023: $860 · 2024: $1,146 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.51 |
| Education | $241.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,248.95 | 2019-2024 | Lokelma, Farxiga |
| Opko Pharmaceuticals, LLC | $839.74 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $784.03 | 2019-2025 | Jynarque |
| Amgen INC. | $475.34 | 2021-2024 | Parsabiv, Tavneos |
| Vifor Pharma, INC. | $443.57 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $430.46 | 2022-2025 | Filspari |
| Ardelyx, INC. | $384.14 | 2023-2025 | Ibsrela |
| Mallinckrodt Enterprises LLC | $221.58 | 2019 | |
| Fresenius USA Marketing, INC. | $163.76 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $144.40 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $134.98 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $98.94 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $81.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $75.52 | 2023-2025 | |
| Genzyme Corporation | $69.68 | 2021-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $65.85 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $43.08 | 2022-2023 | Lupkynis |
| Novo Nordisk INC | $16.70 | 2023 | Rybelsus, Ozempic |
| Shire North American Group INC | $13.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jayachandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.